EPS CAGR:13.73%(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over longer horizons, EPS CAGR averages 2.99% over 3 years and -3.65% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how the company's earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
DGX EPS CAGR Chart
Quest Diagnostics Incorporated (DGX)
DGX Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 20 quarters.
DGX EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $7.80 | $8.87 | +$1.07 | +13.72% | +13.72% |
| 2024 | $7.59 | $7.80 | +$0.21 | +2.77% | +2.77% |
| 2023 | $8.12 | $7.59 | $-0.53 | -6.53% | -6.53% |
| 2022 | $15.90 | $8.12 | $-7.78 | -48.93% | -48.93% |
| 2021 | $10.68 | $15.90 | +$5.22 | +48.88% | +48.88% |
| 2020 | $6.38 | $10.68 | +$4.30 | +67.40% | +67.40% |
| 2019 | $5.41 | $6.38 | +$0.97 | +17.93% | +17.93% |
| 2018 | $5.63 | $5.41 | $-0.22 | -3.91% | -3.91% |
| 2017 | $4.58 | $5.63 | +$1.05 | +22.93% | +22.93% |
| 2016 | $4.92 | $4.58 | $-0.34 | -6.91% | -6.91% |
| 2015 | $3.83 | $4.92 | +$1.09 | +28.46% | +28.46% |
| 2014 | $5.58 | $3.83 | $-1.75 | -31.36% | -31.36% |
| 2013 | $3.49 | $5.58 | +$2.09 | +59.89% | +59.89% |
| 2012 | $2.95 | $3.49 | +$0.54 | +18.31% | +18.31% |
| 2011 | $4.08 | $2.95 | $-1.13 | -27.70% | -27.70% |
| 2010 | $3.91 | $4.08 | +$0.17 | +4.35% | +4.35% |
| 2009 | $2.99 | $3.91 | +$0.92 | +30.77% | +30.77% |
| 2008 | $1.76 | $2.99 | +$1.23 | +69.89% | +69.89% |
| 2007 | $2.98 | $1.76 | $-1.22 | -40.94% | -40.94% |
| 2006 | $2.71 | $2.98 | +$0.27 | +9.96% | +9.96% |
| 2005 | $2.45 | $2.71 | +$0.26 | +10.61% | +10.61% |
| 2004 | $2.11 | $2.45 | +$0.34 | +16.11% | +16.11% |
| 2003 | $1.67 | $2.11 | +$0.44 | +26.35% | +26.35% |
| 2002 | $0.87 | $1.67 | +$0.80 | +91.95% | +91.95% |
| 2001 | $0.57 | $0.87 | +$0.30 | +52.63% | +52.63% |
| 2000 | $-0.03 | $0.57 | +$0.59 | N/A | N/A |
| 1999 | $0.23 | $-0.03 | $-0.26 | -110.87% | N/A |
| 1998 | $-0.19 | $0.23 | +$0.42 | N/A | N/A |
| 1997 | $-5.33 | $-0.19 | +$5.14 | N/A | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $2.27 | +2.7% | +15.2% |
| Q4 2025 | $2.21 | +1.4% | +11.6% |
| Q3 2025 | $2.18 | -13.1% | +8.5% |
| Q2 2025 | $2.51 | +27.4% | +22.4% |
| Q1 2025 | $1.97 | -0.5% | +13.2% |
| Q4 2024 | $1.98 | -1.5% | +15.1% |
| Q3 2024 | $2.01 | -2.0% | +1.0% |
| Q2 2024 | $2.05 | +17.8% | -1.9% |
| Q1 2024 | $1.74 | +1.2% | -2.8% |
| Q4 2023 | $1.72 | -13.6% | +93.3% |
| Q3 2023 | $1.99 | -4.8% | -9.1% |
| Q2 2023 | $2.09 | +16.8% | +5.0% |
| Q1 2023 | $1.79 | +101.1% | -39.7% |
| Q4 2022 | $0.89 | -59.4% | -72.1% |
| Q3 2022 | $2.19 | +10.1% | -46.7% |
| Q2 2022 | $1.99 | -33.0% | -60.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis